10-K: Cryo-Cell International Reports Increased Revenue for Fiscal Year 2024 Amidst Legal Dispute with Duke University

Cryo-Cell International's 10-K filing reveals a 2% revenue increase for fiscal year 2024, overshadowed by an ongoing arbitration with Duke University and strategic shifts in business operations.

Summary

• Cryo-Cell International, Inc., a stem cell storage company, reported a 2% increase in revenue for the fiscal year ended November 30, 2024, with total revenue reaching $31.99 million compared to $31.34 million in the previous year.
• The increase is primarily attributed to a 4% rise in recurring annual storage fee revenue, which was partially offset by a 6% decrease in new domestic cord blood specimens processed.
• The company is currently involved in an arbitration demand against Duke University, alleging fraudulent inducement and breach of contract related to a Patent and Technology License Agreement.
• As a result of the dispute, Cryo-Cell has paused further investments in activities related to the Duke License Agreement, except for a comparability study estimated to cost less than $350,000.
• The opening of the Cryo-Cell Institute for Cellular Therapies is also on hold, and the proposed spinoff of Celle Corp. is uncertain pending the outcome of the Duke dispute.
• The company's cash and cash equivalents increased to $560,960 as of November 30, 2024, compared to $406,067 the previous year.
• The Board of Directors declared a cash dividend of $0.25 per share of common stock, payable to stockholders of record as of February 28, 2025.
• The company has 82 full-time and 4 part-time employees as of November 30, 2024.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While revenue increased, the legal dispute with Duke University and the paused investments create uncertainty. The dividend declaration is a positive sign, but the overall outlook is cautiously neutral.

Positives

• The company experienced a 2% increase in revenue for fiscal year 2024.
• Recurring annual storage fee revenue increased by 4%.
• The company's cash and cash equivalents increased to $560,960 as of November 30, 2024.
• The Board of Directors declared a cash dividend of $0.25 per share of common stock.

Negatives

• The company is involved in an arbitration demand against Duke University, which could have a material adverse effect on the company's business.
• Investments related to the Duke License Agreement are on hold, except for a $350,000 comparability study.
• The opening of the Cryo-Cell Institute for Cellular Therapies is paused.
• The number of new domestic cord blood specimens processed decreased by 6%.

Risks

• The outcome of the arbitration demand against Duke University is uncertain and could negatively impact the company's business.
• The company's ability to expand its business into cord blood and cord tissue infusion clinic services and biopharmaceutical manufacturing is uncertain.
• The stem cell preservation market is increasingly competitive.
• A failure in the performance of the company's cryopreservation storage facility or systems could harm the business and reputation.
• The company may need to raise additional capital.
• The company's operations and performance depend significantly on global and regional economic conditions.

Future Outlook

The company anticipates that its cash and cash equivalents, marketable securities and cash flows from operations, together with external sources of capital will be sufficient to fund its known cash needs for at least the next 12 months. However, cash flows from operations will depend primarily upon increasing revenues from sales of its umbilical cord blood and cord tissue cellular storage services and managing discretionary expenses.

Management Comments

• The Company currently stores over 240,000 cord blood and cord tissue specimens for the exclusive benefit of newborn babies and possibly other members of their families.
• The Company has notified Duke that it believes such damages exceed $100 million.

Industry Context

The stem cell preservation market is increasingly competitive, with approximately 25 other national private cord blood banks. The company believes that its longevity and experience; value-based pricing strategy; superior customer service; premier technical and operational expertise; state-of-the-art facilities; innovative marketing programs and its expansive client base will continue to provide a competitive advantage.

Comparison to Industry Standards

• The document does not provide enough information to make a detailed comparison to industry standards.
• Comparable companies in the cord blood banking industry include Cord Blood Registry (CBR), ViaCord, and Americord Registry.
• Without specific financial metrics from these companies for the same period, a direct comparison is not possible.
• However, the document highlights Cryo-Cell's AABB accreditation and cGMP/cGTP-compliant facility, which are considered industry quality benchmarks.

Legal Proceedings

• The Company is involved in a legal proceeding styled Lindsey Lehr v. Cryo-Cell International, Inc.
• The Company is involved in an arbitration demand against Duke University.

Related Party Transactions

• David Portnoy, the Company's Chairman and Co-Chief Executive officer, is the brother of the Company's Co-Chief Executive Officer Mark Portnoy.
• The Company's Audit Committee Chairman, Harold Berger, provides accounting services to the Company's Co-Chief Executive Officer Mark Portnoy and to PartnerCommunity, Inc.
• The Company's Chairman and Co-Chief Executive Officer, David Portnoy, serves as the Chairman of the Board of PartnerCommunity, Inc.

Stakeholder Impact

• Shareholders may be impacted by the outcome of the arbitration demand against Duke University and the company's ability to generate future revenue.
• Employees may be impacted by the company's strategic shifts and potential changes in business operations.
• Customers may be impacted by the company's ability to provide innovative stem cell preservation services.

Next Steps

• The company will continue to pursue its arbitration demand against Duke University.
• The company will complete a comparability study related to the Duke License Agreement.
• The company will monitor the stem cell preservation market and adjust its strategies as needed.
• The company will continue to evaluate and pursue certain opportunities for global expansion, on a selective basis, in which operational synergies and economic potential align with Cryo-Cells strategic direction.

Key Dates